BB Biotech

Swiss Investment Company - the access to fast growing biotech companies

[BB Biotech @BB_Biotech_AG]

🔎 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐢𝐧𝐠 𝐞𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐢𝐧 𝐜𝐨𝐦𝐩𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭

Download the full publication and discuss the future of computational drug development with us: https://t.co/jLtxLJJFMq

#DrugDevelopment

[BB Biotech @BB_Biotech_AG]

🔬 BB Biotech Update: Insights, highlights and outlook🚀
Join Daniel Koller as he explores the #biotech sector's 2023 developments, BB Biotech's Q4 strategies, JP Morgan Conference insights, recent M&As, and 2024 outlook in our latest video.

Watch now ⬇️
https://t.co/06aEQ0WLI7

[BB Biotech @BB_Biotech_AG]

«Diversifikation spielt eine wichtige Rolle für den Unternehmenswert»

Daniel Koller, Head Investment Management Team BB Biotech im Interview mit https://t.co/Nv6LgUDqPh.

https://t.co/aZcNc4OLGg

#Biotech

[BB Biotech @BB_Biotech_AG]

🎙️ Biotech investing, mRNA and genome editing 👇
Daniel Koller spoke on the Art of Investment Podcast about the long-term growth drivers underlying the biotech sector and some applications of breakthrough mRNA technology and genome editing.

https://t.co/x6FfHDWnUe

[BB Biotech @BB_Biotech_AG]

BB Biotech shares ended the quarter with a negative return of 6.9% in CHF and 4.7% in EUR. This contrasts with the change in portfolio Net Asset Value (NAV), which increased by 8.3% in CHF, 12.1% in EUR and 4.8% in USD over the same period.

https://t.co/98sNOUd5oi

[BB Biotech @BB_Biotech_AG]

🎙️ Daniel Koller im Gespräch mit DUP Digital Business Talk.

#Biotechinvestments

https://t.co/QIbHbRGRpq

[Rivus Pharmaceuticals @RivusPharma]

We are thrilled to announce completion of a $132 million Series B financing. This funding supports clinical advancement of lead candidate HU6, a #CMA designed to treat #Cardiometabolic disease and #obesity.
Access the full release here: https://t.co/iJDASEXUpP

[BB Biotech @BB_Biotech_AG]

🔎 Aktueller Marktkommentar: Moderna war erst der Anfang
Wie #RNA-basierte Arzneien in den nächsten Jahren die gentherapeutische Behandlung von immer mehr Krankheiten revolutionieren. Mehr dazu 👇

https://t.co/kf8IKQ6RnG

[BB Biotech @BB_Biotech_AG]

In the second quarter a loss of CHF 233 mn (profit of CHF 129 mn in the corresponding period of the previous year) was incurred. Many portfolio companies reach new milestones. Increase in M&A expected over the coming year or beyond.

https://t.co/BTq2qoDBZQ

#BiotechInvestments

[BB Biotech @BB_Biotech_AG]

🔎 Marktkommentar: Begehrte Innovationstreiber
Treibende Kraft bei vielen neuen therapeutischen Ansätzen für Arzneien und zugleich an den Börsen niedrig bewertet – die #Biotechbranche durchläuft eine paradoxe Entwicklungsphase.

https://t.co/SayhDkqOrf

#Biotechinvestments

[BB Biotech @BB_Biotech_AG]

BB Biotech-Investmentchef Daniel Koller sieht die Pharmabranche vor einer Übernahmewelle im Herbst. Mehr dazu im Interview mit BÖRSE ONLINE 👇

https://t.co/zP2G3VOR2R

#Biotechinvestments #M&A

[BB Biotech @BB_Biotech_AG]

Coveted drivers of innovation.

BB Biotech’s Koller asks what lies ahead for #M&A activity in the #biotech sector? Read more on Wealth DFM. 👇

https://t.co/nuhrzsQVxJ

#biotechnology #investments

[BB Biotech @BB_Biotech_AG]

It was great to attend the «MID & SMALL VIRTUAL 2022» conference of Virgilio IR yesterday, meeting institutional investors.

#biotechinvestments

[BB Biotech @BB_Biotech_AG]

BB Biotech in @EuroamSonntag
https://t.co/FC2BjdBOXm

[BB Biotech @BB_Biotech_AG]

New market commentary: #Disruptive #technologies are changing an entire industry. How? Find out more 👇🏼

https://t.co/mZvrZZwJ72

#biotechinvestments

[BB Biotech @BB_Biotech_AG]

#Biotech sector sees potential for growth post Covid.

🎙️ #Interview with portfolio manager Dallas Webb in wealth adviser.

https://t.co/pUV29DKY3Z

#Biotechnology #investments

[BB Biotech @BB_Biotech_AG]

Interim report of BB Biotech AG as at March 31, 2022 👇
https://t.co/dfQUyFF2ko

[BB Biotech @BB_Biotech_AG]

BB Biotech AG published its #annualreport for fiscal year 2021 today incl. the audited consolidated financial statements, detailed information on the #biotechnology sector and its first, unaudited #ESG report.

https://t.co/82naDWNmYp

[BB Biotech @BB_Biotech_AG]

🌐 Our NEW website makes it easier than ever to browse through the BB Biotech portfolio, get the latest news and see the performance.

👇👇

https://t.co/XonzwkLK8c

#bbbiotech #biotechnology #newlook

[BB Biotech @BB_Biotech_AG]

The year 2021 was a volatile market environment for all involved in #biotechnology investing, including BB Biotech.

The challenging biotechnology equity market resulted in a net loss for BB Biotech in 2021 of CHF 405 mn.

Read the full press release: https://t.co/b0eDuw19Hd